Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
Anahit Mkrtchian, Jennifer W. Evans, Christoph Kraus, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 7, pp. 3292-3301
Open Access | Times Cited: 83

Showing 26-50 of 83 citing articles:

Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine
Artemis Zavaliangos‐Petropulu, Noor Al‐Sharif, Brandon Taraku, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2022) Vol. 8, Iss. 4, pp. 361-386
Open Access | Times Cited: 17
Review: The use of functional magnetic resonance imaging (fMRI) in clinical trials and experimental research studies for depression
Vasileia Kotoula, Jennifer W. Evans, Claire Punturieri, et al.
Frontiers in Neuroimaging (2023) Vol. 2
Open Access | Times Cited: 10
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli, et al.
Brain Sciences (2023) Vol. 13, Iss. 10, pp. 1494-1494
Open Access | Times Cited: 9
The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
Angela T.H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, et al.
Journal of Affective Disorders (2024) Vol. 360, pp. 421-426
Closed Access | Times Cited: 3
Neural plasticity and depression treatment
Yubing Wang, Ning‐Ning Song, Yu‐Qiang Ding, et al.
IBRO Neuroscience Reports (2022) Vol. 14, pp. 160-184
Open Access | Times Cited: 15
Pharmacological Treatments for Anhedonia
Matthew Klein, Ariela Buxbaum Grice, Sahil Sheth, et al.
Current topics in behavioral neurosciences (2022), pp. 467-489
Closed Access | Times Cited: 14
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
Artemis Zavaliangos‐Petropulu, Shawn M. McClintock, Jacqueline Khalil, et al.
Journal of Affective Disorders (2023) Vol. 333, pp. 161-171
Open Access | Times Cited: 8
Assessment of Initial Depressive State and Pain Relief With Ketamine in Patients With Chronic Refractory Pain
Marion Voute, Céline Lambert, Bruno Pereira, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314406-e2314406
Open Access | Times Cited: 8
Functional MRI markers for treatment-resistant depression: Insights and challenges
Vasileia Kotoula, Jennifer W. Evans, Claire Punturieri, et al.
Progress in brain research (2023), pp. 117-148
Open Access | Times Cited: 8
Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals
Laith Alexander, Peter C.T. Hawkins, Jennifer W. Evans, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology
Alexandra Alario, Mark J. Niciu
Chronic Stress (2021) Vol. 5, pp. 247054702110142-247054702110142
Open Access | Times Cited: 18
Altered functional connectivity in first-episode and recurrent depression: A resting-state functional magnetic resonance imaging study
Jifei Sun, Zhongming Du, Yue Ma, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 13
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study
Bruno Pedraz‐Petrozzi, Moritz Spangemacher, Anton Deicher, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Effects of chronic stress on cognitive function – From neurobiology to intervention
Milena Girotti, Sarah E. Bulin, Flavia Carreño
Neurobiology of Stress (2024) Vol. 33, pp. 100670-100670
Open Access | Times Cited: 2
Resting-state connectivity studies as a marker of the acute and delayed effects of subanaesthetic ketamine administration in healthy and depressed individuals: A systematic review
Vasileia Kotoula, Toby Webster, James Stone, et al.
Brain and Neuroscience Advances (2021) Vol. 5
Open Access | Times Cited: 16
The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
Giordano Novak Rossi, Jaime E. C. Hallak, Glen B. Baker, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 273, Iss. 1, pp. 129-155
Closed Access | Times Cited: 10
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability
Michael D. Kritzer, Chi‐Un Pae, Prakash S. Masand
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 725-732
Open Access | Times Cited: 9
Functional ultrasound detects frequency-specific acute and delayed S-ketamine effects in the healthy mouse brain
Tudor M. Ionescu, Gillian Grohs-Metz, Bastian Hengerer
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 5
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Liang Zhou, Jingjing Duan
CNS Neuroscience & Therapeutics (2023) Vol. 30, Iss. 4
Open Access | Times Cited: 5
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression
Ezio Carboni, Anna R. Carta
Journal of Integrative Neuroscience (2022) Vol. 21, Iss. 5
Open Access | Times Cited: 8
Altered dynamic amplitude of low‐frequency fluctuation in individuals at high risk for Alzheimer's disease
Qin‐qin Zhu, Shui Tian, Ling Zhang, et al.
European Journal of Neuroscience (2024) Vol. 59, Iss. 9, pp. 2391-2402
Closed Access | Times Cited: 1
Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders
Keshav Juneja, Sabah Afroze, Zeel Goti, et al.
Discover Mental Health (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Persistent Brain Connectivity Changes in Healthy Volunteers Following Nitrous Oxide Inhalation
Ben Julian A. Palanca, Charles R. Conway, Thomas A. Zeffiro, et al.
Biological Psychiatry Global Open Science (2023) Vol. 3, Iss. 4, pp. 698-704
Open Access | Times Cited: 4
Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review
Thi Mai Loan Nguyen, Fabrice Jollant, Laurent Tritschler, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 634-634
Open Access | Times Cited: 4

Scroll to top